XML 59 R48.htm IDEA: XBRL DOCUMENT v3.25.2
Stockholders' Equity (Deficit) (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Mar. 23, 2025
USD ($)
$ / shares
shares
Dec. 02, 2024
USD ($)
$ / shares
shares
Jul. 22, 2024
USD ($)
$ / shares
shares
Jan. 22, 2024
USD ($)
$ / shares
shares
Jun. 09, 2023
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Mar. 31, 2025
shares
Jun. 30, 2024
shares
Mar. 31, 2024
shares
Jun. 30, 2025
USD ($)
Vote
$ / shares
shares
Jun. 30, 2024
USD ($)
Dec. 31, 2024
$ / shares
shares
Feb. 25, 2025
$ / shares
shares
Jan. 31, 2024
$ / shares
shares
Feb. 16, 2023
$ / shares
shares
Stockholders' Equity                              
Maximum number of shares which the Company is authorized to issue                   300,000,000          
Preferred stock, par value (in dollars per share) | $ / shares                   $ 0.0001   $ 0.0001      
Preferred Stock, Shares Issued                   0   0      
Common stock, shares issued                   833,683   36,753      
Common stock, share outstanding                   833,683   36,753      
Net proceeds from sales of common stock | $                   $ 8,854,797 $ 6,872,339        
Common Stock - Dividends and Voting                              
Cash dividends were declared or paid | $                   $ 0          
Common stock voting rights per share | Vote                   1          
Series C warrants                              
Stockholders' Equity                              
Term of warrants                         5 years    
Exercise price | $ / shares                   $ 69.67     $ 438.9    
Number of warrants purchased                   144,678          
Series D warrants                              
Stockholders' Equity                              
Term of warrants                         2 years 6 months    
Exercise price | $ / shares                         $ 438.90    
Series A-1 Warrants                              
Stockholders' Equity                              
Term of warrants         3 years                    
Exercise price | $ / shares         $ 348.35                    
Issuances of common stock, net (in shares)         55                    
Series A-2 Warrants                              
Stockholders' Equity                              
Term of warrants         3 years                    
Exercise price | $ / shares         $ 348.35                    
Issuances of common stock, net (in shares)         55                    
June Placement Agent Warrants                              
Stockholders' Equity                              
Term of warrants         3 years                    
Exercise price | $ / shares         $ 161,700                    
Number of warrants purchased         4                    
February Placement Agent Warrants                              
Stockholders' Equity                              
Exercise price | $ / shares                             $ 486,948
Number of warrants purchased                             1
December Placement Agent Warrants                              
Stockholders' Equity                              
Number of warrants sold           9                  
Term of warrants           5 years                  
Exercise price | $ / shares           $ 11,180.4                  
January Warrants                              
Stockholders' Equity                              
Term of warrants                           3 years 6 months  
Exercise price | $ / shares                           $ 1,127.28  
Number of warrants purchased                           12,864  
January Placement Agent Warrants                              
Stockholders' Equity                              
Term of warrants                           3 years 6 months  
Exercise price | $ / shares                   $ 1,409.1       $ 1,409.1  
Number of warrants purchased                   386       386  
Securities Purchase Agreement                              
Stockholders' Equity                              
Aggregate of direct offering       465                      
Price per share (in dollars per share) | $ / shares   $ 348.35   $ 1,127.28                      
Net proceeds from sales of common stock | $   $ 7,200,000   $ 6,100,000                      
Issuances of common stock, net (in shares)   6,180                          
Securities Purchase Agreement | Series C warrants                              
Stockholders' Equity                              
Number of warrants sold   22,966                   22,966      
Term of warrants   5 years                          
Exercise price | $ / shares   $ 438.9                          
Securities Purchase Agreement | Series D warrants                              
Stockholders' Equity                              
Number of warrants sold   22,966                   22,966      
Exercise price | $ / shares   $ 438.90                          
Purchase of common stock   3                     3    
Securities Purchase Agreement | Pre-funded warrants                              
Stockholders' Equity                              
Number of warrants sold   16,786   5,968                      
Price per share (in dollars per share) | $ / shares   $ 348.25   $ 1,118.04                      
Exercise price | $ / shares   $ 0.0924   $ 9.24                      
Securities Purchase Agreement | January Warrants                              
Stockholders' Equity                              
Number of warrants sold       12,864                      
Term of warrants       3 years 6 months                      
Exercise price | $ / shares       $ 1,127.28                      
Securities Purchase Agreement | January Placement Agent Warrants                              
Stockholders' Equity                              
Term of warrants       3 years 6 months                      
Exercise price | $ / shares       $ 1,409.1                      
Number of warrants purchased       386                      
July 2024 Offering                              
Stockholders' Equity                              
Net proceeds from sales of common stock | $     $ 2,400,000                        
Issuances of common stock, net (in shares)     10,823                        
Purchase price of per share | $ / shares     $ 277.2                        
July 2024 Offering | July Placement Agent Warrants                              
Stockholders' Equity                              
Exercise price | $ / shares     $ 346.5                        
Number of warrants purchased     542                        
March 2025 Registered Direct Offering                              
Stockholders' Equity                              
Price per share (in dollars per share) | $ / shares $ 27.44                            
Issuances of common stock, net (in shares) 366,072                            
Gross proceeds | $ $ 8,900,000                            
March 2025 Registered Direct Offering | Common Stock Purchase Warrants                              
Stockholders' Equity                              
Exercise price | $ / shares $ 24.08                            
March 2025 Registered Direct Offering | Placement agent warrants from February RDO                              
Stockholders' Equity                              
Exercise price | $ / shares $ 29.96                            
Number of warrants purchased 366,072                            
Common Stock                              
Stockholders' Equity                              
Maximum number of shares which the Company is authorized to issue                   290,000,000          
Issuances of common stock, net (in shares) [1]             796,930 1,577 5,607            
Preferred Stock                              
Stockholders' Equity                              
Maximum number of shares which the Company is authorized to issue                   10,000,000          
[1] On May 15, 2025, the Company effected a reverse split of the Company's common stock, either issued and outstanding or held by the Company as treasury stock. The May 2025 Reverse Split was at a ratio of one share for every 28 shares previously held with no change in the par value per share. The May 2025 Reverse Split did not change the number of authorized shares of common stock. All common stock share and per share data, and exercise price data for applicable common stock equivalents, included in these financial statements have been retroactively adjusted to reflect the Reverse Split.